Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/24516
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKhor, Yet H-
dc.contributor.authorNg, Yvonne-
dc.contributor.authorBarnes, Hayley-
dc.contributor.authorGoh, Nicole S L-
dc.contributor.authorMcDonald, Christine F-
dc.contributor.authorHolland, Anne E-
dc.date2020-08-04-
dc.date.accessioned2020-09-28T20:42:01Z-
dc.date.available2020-09-28T20:42:01Z-
dc.date.issued2020-09-30-
dc.identifier.citationEuropean Respiratory Review 2020; 29(157): 190158en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/24516-
dc.description.abstractIn addition to facilitating healthcare delivery planning, reliable information about prognosis is essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This review aimed to evaluate the prognosis of patients with IPF without anti-fibrotic therapy. We included all cohort studies and the placebo arms of randomised controlled trials (RCTs) in IPF and follow-up of ≥12 months. Two reviewers independently evaluated studies for inclusion, assessed risk of bias and extracted data. A total of 154 cohort studies and 16 RCTs were included. The pooled proportions of mortality were 0.12 (95% CI 0.09-0.14) at 1-2 years, 0.38 (95% CI 0.34-0.42) between 2-5 years, and 0.69 (95% CI 0.59-0.78) at ≥5 years. The pooled mean overall survival was 4 years (95% CI 3.7-4.6) for studies with a follow-up duration of 10 years. At <2 years, forced vital capacity and diffusing capacity of the lung for carbon monoxide declined by a mean of 6.76% predicted (95% CI -8.92 -4.61) and 3% predicted (95% CI -5.14 -1.52), respectively. Although heterogeneity was high, subgroup analyses revealed lower pooled proportions of mortality at 1 year in the RCT participants (0.07 (95% CI 0.05-0.09)) versus cohort study participants (0.14 (95% CI 0.12-0.17)). This review provides comprehensive information on the prognosis of IPF, which can inform treatment discussions with patients and comparisons for future studies with new therapies.en
dc.language.isoeng
dc.titlePrognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean Respiratory Reviewen
dc.identifier.affiliationRespiratory and Sleep Medicineen
dc.identifier.affiliationInstitute for Breathing and Sleepen
dc.identifier.affiliationDept of Respiratory Medicine, Alfred Health, Melbourne, Australiaen
dc.identifier.affiliationSchool of Medicine, University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationDept of Respiratory Medicine, Alfred Health, Melbourne, Australiaen
dc.identifier.affiliationDept of Physiotherapy, Alfred Health and Monash University, Melbourne, Australiaen
dc.identifier.affiliationDept of Respiratory Medicine, Alfred Health, Melbourne, Australiaen
dc.identifier.affiliationMonash Lung and Sleep, Monash Health, Clayton, Australiaen
dc.identifier.doi10.1183/16000617.0158-2019en
dc.type.contentTexten
dc.identifier.orcid0000-0002-5434-9342en
dc.identifier.orcid0000-0002-7615-4191en
dc.identifier.orcid0000-0003-2061-845Xen
dc.identifier.pubmedid32759374
local.name.researcherGoh, Nicole S L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptPhysiotherapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

50
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.